Juan Ignacio Rojas1,2, Marina Alonso Serena3, Orlando Garcea4, Liliana Patrucco5, Adriana Carrá6,7, Jorge Correale8, Carlos Vrech9, Agustín Pappolla5, Jimena Miguez5, María L Doldan5,10, Facundo Silveira5, Ricardo Alonso4,11, Leila Cohen4, Cecilia Pita4, Berenice A Silva4, Marcela Fiol8, María I Gaitán8, Mariano Marrodan8, Laura Negrotto8, María C Ysrraelit8, Norma Deri12, Geraldine Luetic13, Alejandro Caride14, Edgar Carnero Contentti14, Pablo A Lopez14, Juan Pablo Pettinicchi14, Celeste Curbelo6,15, Alejandra D Martinez6, Judith D Steinberg6, María E Balbuena16, Verónica Tkachuk16, Marcos Burgos17, Eduardo Knorre18, Felisa Leguizamon18, Raúl Piedrabuena19,20, Susana Del V Liwacki19,21, Andrés G Barboza22, Pedro Nofal23, Gabriel Volman24, Amelia Alvez Pinheiro25, Javier Hryb26, Dario Tavolini27, Patricio A Blaya28, Emanuel Silva29, Jorge Blanche30, Santiago Tizio31, Fernando Caceres32, María Laura Saladino32, Gisela Zanga33, María E Fracaro34, Gustavo Sgrilli35, Fátima Pagani Cassara36, Guido Vazquez7, Vladimiro Sinay36, María Laura Menichini37, Luciana Lazaro11, Lorena M Cabrera38,39, Santiago Bestoso40, Pablo Divi41, Miguel Jacobo41, Eduardo Kohler42, Matías Kohler42, Diego Giunta3, Carolina Mainella43, Ruben Manzi44, Marcela Parada Marcilla45, Juan Pablo Viglione46, Ivan Martos47, Edgardo Reich48, Gustavo Jose49, Edgardo Cristiano5,10, Nora Fernández Liguori11,50. 1. Servicio de Neurología, Hospital Italiano de Buenos Aires, Perón 4190, CABA, Buenos Aires, Argentina. rojasjuanignacio@gmail.com. 2. Centro de Esclerosis Múltiple de Buenos Aires, Buenos Aires, Argentina. rojasjuanignacio@gmail.com. 3. Área de Investigación en Medicina Interna, Hospital Italiano de Buenos Aires, CABA, Argentina. 4. Centro Universitario de Esclerosis Múltiple, Facultad de Medicina - UBA, Hospital Dr. J. M. Ramos Mejía, CABA, Argentina. 5. Servicio de Neurología, Hospital Italiano de Buenos Aires, Perón 4190, CABA, Buenos Aires, Argentina. 6. Sección de Enfermedades Desmielinizantes, Hospital Británico, CABA, Argentina. 7. Fundación Favaloro/INECO, CABA, Argentina. 8. Departamento de Neurología, FLENI, CABA, Argentina. 9. Departamento de Enfermedades desmielinizantes, Sanatorio Allende, Córdoba, Argentina. 10. Centro de Esclerosis Múltiple de Buenos Aires, Buenos Aires, Argentina. 11. Sanatorio Güemes, CABA, Argentina. 12. Centro de Investigaciones Diabaid, CABA, Argentina. 13. Instituto de Neurociencias de Rosario, Santa Fe, Argentina. 14. Unidad de Neuroinmunología, Departamento de Neurociencias, Hospital Alemán de Buenos Aires, CABA, Argentina. 15. Policlínico Municipal Sofía T. de Santamarina, Buenos Aires, Argentina. 16. Sección de Neuroinmunología y Enfermedades Desmielinizantes, Servicio de Neurología, Hospital de Clínicas José de San Martín, CABA, Argentina. 17. Servicio de Neurología, Hospital San Bernardo, Salta, Argentina. 18. Hospital de Agudos, Dr. Teodoro Álvarez, CABA, Argentina. 19. Clínica Universitaria Reina Fabiola, Córdoba, Argentina. 20. Instituto Lennox, Córdoba, Argentina. 21. Servicio de Neurología, Hospital Córdoba, Córdoba, Argentina. 22. Hospital Central de Mendoza, Mendoza, Argentina. 23. Hospital de Clínicas Nuestra Señora del Carmen, San Miguel de Tucumán, Tucumán, Argentina. 24. Hospital Presidente Perón de Avellaneda, Buenos Aires, Argentina. 25. Hospital San Martín, Paraná, Entre Ríos, Argentina. 26. Servicio de Neurología, Hospital Carlos G Durand, CABA, Argentina. 27. INECO Neurociencias Oroño - Fundación INECO, Rosario, Santa Fe, Argentina. 28. Neurocomp, Trelew, Chubut, Argentina. 29. Predigma - Centro de Medicina Preventiva, Posadas, Misiones, Argentina. 30. IRNEC (Instituto Regional de Neurociencias), San Miguel de Tucuman, Argentina. 31. Hospital Español de la Plata, Buenos Aires, Argentina. 32. INEBA, Institute of Neuoscience Buenos Aires, Buenos Aires, Argentina. 33. Unidad asistencial César Milstein, CABA, Argentina. 34. Clinica el Castaño, San Juan, Argentina. 35. Axis Neurociencias, Bahía Blanca, Buenos Aires, Argentina. 36. Instituto de Neurociencias, Fundación Favaloro/INECO, CABA, Argentina. 37. Sanatorio Británico, Rosario, Santa Fe, Argentina. 38. Servicio de Neurología, Hospital Militar Central, CABA, Argentina. 39. Hospital Militar Campo de Mayo, CABA, Argentina. 40. Servicio Neurología, Hospital Escuela José F. de San Martín Corrientes, Corrientes, Argentina. 41. RIAPEM (Red Integral Asistencial al Paciente con Esclerosis Múltiple), Santiago del Estero, Argentina. 42. Fundación Sinapsis Santa Rosa, Santa Rosa, La Pampa, Argentina. 43. Hospital Español de Rosario, Rosario, Argentina. 44. Sanatorio Pasteur, Catamarca, Argentina. 45. Servicio de Neurología, Clínica Bazterrica, Buenos Aires, Argentina. 46. Clinica Regional del Sud, Río Cuarto, Córdoba, Argentina. 47. Clinica San Jorge. Ushuaia. Tierra del fuego, Ushuaia, Argentina. 48. Servicio de Neurologia, Hospital Municipal Dr. Julio Mendez, Buenos Aires/Centro de Neurociencias Universidad Maimonides, Buenos Aires, Argentina. 49. Sección de enfermedades desmielinizantes, Servicio de Neurología, Hospital Padilla, Tucumán, Argentina. 50. Hospital Enrique Tornú, Buenos Aires, Argentina.
Abstract
The objective of this study was to describe and compare the baseline epidemiological data of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) patients included in RelevarEM (Clinical Trials registry number NCT03375177). METHODS: RelevarEM is a longitudinal, strictly observational MS and NMOSD registry in Argentina. Epidemiological and comorbidity data from MS and NMOSD patients were described and compared. For comorbidities, the Charlson comorbidity index (CCI) was used to calculate the burden at entry. CCI was stratified in 0 and ≥ 1 and described for the entire cohort. RESULTS: A total of 1588 and 75 MS and NMOSD patients (respectively) were included. For MS patients, the mean age was 42 ± 7 years, female sex 65.3%, mean EDSS 2, and mean disease duration 8 ± 6 years. In NMOSD, the mean age was 40 ± 7 years, female sex 78.7%, mean disease duration 5 ± 3.5 years, and mean EDSS 2.5. The most frequent MS phenotype was RRMS in 82.4%. In MS, the CCI was 0 in 85.8.2% while ≥ 1 was in 14.2% of patients. Regarding phenotype stratification, CCI ≥ 1 was 3.9% in CIS, 13.5% in RRMS, 28.7% in SPMS, and 17.4% in PPMS (p < 0.001 between groups). In NMOSD, the CCI was 0 in 64% while ≥ 1 was in 36%. The MS/NMOSD ratio found was 21/1. CONCLUSIONS: This is the first analysis of the longitudinal Argentinean registry of MS and NMOSD describing and comparing conditions that contributes to provide reliable real-world data in the country.
The objective of this study was to describe and compare the baseline epidemiological data of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) patients included in RelevarEM (Clinical Trials registry number NCT03375177). METHODS: RelevarEM is a longitudinal, strictly observational MS and NMOSD registry in Argentina. Epidemiological and comorbidity data from MS and NMOSDpatients were described and compared. For comorbidities, the Charlson comorbidity index (CCI) was used to calculate the burden at entry. CCI was stratified in 0 and ≥ 1 and described for the entire cohort. RESULTS: A total of 1588 and 75 MS and NMOSDpatients (respectively) were included. For MSpatients, the mean age was 42 ± 7 years, female sex 65.3%, mean EDSS 2, and mean disease duration 8 ± 6 years. In NMOSD, the mean age was 40 ± 7 years, female sex 78.7%, mean disease duration 5 ± 3.5 years, and mean EDSS 2.5. The most frequent MS phenotype was RRMS in 82.4%. In MS, the CCI was 0 in 85.8.2% while ≥ 1 was in 14.2% of patients. Regarding phenotype stratification, CCI ≥ 1 was 3.9% in CIS, 13.5% in RRMS, 28.7% in SPMS, and 17.4% in PPMS (p < 0.001 between groups). In NMOSD, the CCI was 0 in 64% while ≥ 1 was in 36%. The MS/NMOSD ratio found was 21/1. CONCLUSIONS: This is the first analysis of the longitudinal Argentinean registry of MS and NMOSD describing and comparing conditions that contributes to provide reliable real-world data in the country.
Authors: Juan Ignacio Rojas; Liliana Patrucco; Maria Trojano; Alessandra Lugaresi; Guillermo Izquierdo; Helmut Butzkueven; Vilija Jokubaitis; Pierre Duquette; Marc Girard; Francois Grand'Maison; Pierre Grammond; Celia Oreja-Guevara; Raymond Hupperts; Cavit Boz; Thor Petersen; Roberto Bergamaschi; Giorgio Giuliani; Jeannette Lechner-Scott; Michael Barnett; Maria Edite Rio; Vincent Van Pesch; Maria Pia Amato; Gerardo Iuliano; Marcela Fiol; Mark Slee; Freek Verheul; Ricardo Fernandez-Bolanos; Dieter Poehlau; Maria Laura Saladino; Leontien Den Braber-Moerland; Norma Deri; Walter Oleschko-Arruda; Jose Antonio Cabrera-Gomez; Mark Paine; Norbert Vella; Ilya Kister; Eli Skromne; Aldo Savino; Cameron Shaw; Fraser Moore; Steve Vucic; Tatjana Petkovska-Boskova; Elizabeth Alejandra Bacile Bacile; Vetere Santiago; Edgardo Cristiano Journal: Mult Scler J Exp Transl Clin Date: 2015-08-17
Authors: Edgar Carnero Contentti; Pablo A Lopez; Juan Pablo Pettinicchi; Juan Criniti; Agustín Pappolla; Jimena Miguez; Liliana Patrucco; Edgardo Carnero Contentti; Susana Liwacki; Verónica Tkachuk; María E Balbuena; Carlos Vrech; Norma Deri; Jorge Correale; Mariano Marrodan; María C Ysrraelit; Felisa Leguizamon; Geraldine Luetic; María L Menichini; Darío Tavolini; Carolina Mainella; Gisela Zanga; Marcos Burgos; Javier Hryb; Andrés Barboza; Luciana Lazaro; Ricardo Alonso; Nora Fernández Liguori; Débora Nadur; Aníbal Chercoff; Marina Alonso Serena; Alejandro Caride; Friedemann Paul; Juan I Rojas Journal: Mult Scler J Exp Transl Clin Date: 2021-08-20